Izalontamab brengitecan for HR+/HER2– breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial

Bo Lan, Yehui Shi, Xiying Shao, Fan Wu, Shusen Wang, Weimin Xie, Qingyuan Zhang, Quchang Ouyang, Jiuwei Cui, Xiaoling Ling, Haijun Yu, Huihui Li, Xianjun Tang, Sijuan Ding, Chunfang Hao, Bing Zhao, Yang Li, Hua Yang, Min Yan, Guohui Han, Xujuan Wang, Fanfan Li, Peijian Peng, Chang Gong, Yunjiang Liu, Junlan Guo, Yongmei Yin, Man Li, Yue’e Teng, Jiuda Zhao, Yongli Gao, Jingfen Wang, Jing Luo, Xinghua Han, Xiaoping Li, Bin Liu, Shuqun Zhang, Bihui Li, Lei Yang, Sa Xiao

DOI: 10.1016/s0140-6736(26)02096-9

На странице источника доступны аннотация, полный текст или сведения о том, где его прочитать.